{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009386","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.658753+00:00","generated_at":"2026-05-25T05:48:52.276370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xtant Medical reports 28% revenue growth in FY2024; guides FY2025 revenue $126M-$130M","bullets":["Revenue $117.3M FY2024, up 28% YoY; Q4 revenue $31.5M, up 12%.","Net loss FY2024 $16.4M ($0.12/share) vs prior year net income $660k (incl $11.7M bargain gain).","Adjusted EBITDA loss FY2024 $2.3M vs loss $1.4M; Q4 positive $438k vs loss $695k.","Guidance: FY2025 revenue $126M-$130M (7-11% organic growth); expects free cash flow in H2 2025.","Post-year-end manufacturing/license deal for SimpliGraft: $1.5M upfront, minimum purchase obligations; annualized cost reductions >$5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009386","json":"https://secwatch.observer/filing/0001493152-25-009386.json","markdown":"https://secwatch.observer/filing/0001493152-25-009386.md","text":"https://secwatch.observer/filing/0001493152-25-009386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225009386/0001493152-25-009386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315225009386/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T05:48:52.276370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}